BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.61 USD
+0.04 (6.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.62 +0.01 (1.37%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for BioLineRx Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 0 | 0 | 0 | 0 |
Cost Of Goods | 4 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 51 | 29 | 25 | 23 | 28 |
Income After Depreciation & Amortization | -50 | -29 | -25 | -23 | -28 |
Non-Operating Income | -9 | 6 | -1 | -5 | 5 |
Interest Expense | 2 | 2 | 1 | 2 | 2 |
Pretax Income | -61 | -25 | -27 | -30 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -61 | -25 | -27 | -30 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -61 | -25 | -27 | -30 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -48 | -29 | -24 | -22 | -27 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -50 | -29 | -25 | -23 | -28 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 64.22 | 51.60 | 44.20 | 16.86 | 9.98 |
Diluted EPS Before Non-Recurring Items | -0.94 | -0.48 | -0.60 | -1.80 | -2.55 |
Diluted Net EPS (GAAP) | -0.90 | -0.45 | -0.60 | -1.80 | -2.55 |
Fiscal Year end for BioLineRx Ltd falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 4.80 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 3.69 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.11 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 12.97 | 12.36 | 9.92 | 8.85 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -11.86 | -12.36 | -9.92 | -8.85 |
Non-Operating Income | NA | 3.75 | -2.83 | -7.29 | -2.38 |
Interest Expense | NA | -0.93 | 0.84 | 1.34 | 0.93 |
Pretax Income | NA | -13.88 | -16.02 | -18.55 | -12.16 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -13.88 | -16.02 | -18.55 | -12.16 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -13.88 | -16.02 | -18.55 | -12.16 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 92.56 | 61.94 | 61.53 | 81.08 |
Diluted EPS Before Non-Recurring Items | NA | -0.15 | -0.30 | -0.30 | -0.15 |
Diluted Net EPS (GAAP) | NA | -0.15 | -0.30 | -0.30 | -0.15 |